• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

D600-0649

(CAS: 1160266-14-7 )

Suppliers of D600-0649

Company Name Email Tel Country
AMEDCHEM [email protected]dchem.com +862168061059 CHINA

Fax: Purity: Brand:

Inquiry Online

Salutation: *Country:
*Customer: *Company Name:
*Email: *Request quantity:
Remarks:
 

Notice: Your contact information will be sent to selected suppliers.

* Required Fields.

Background Information of D600-0649

D600-0649 is a novel cyclin-dependent kinase 8 (CDK8) inhibitor. The inhibition rate is 41.0±2.8% at 10 μM. CDK8 gene expression correlates with increased mortality in colorectal, breast, and ovarian cancers and its overexpression is essential for the proliferation of cancer cells. Due to its key roles in oncogenesis, CDK8 has recently attracted considerable attention. Inhibitors of CDK8 offer a novel strategy for the treatment of various cancers.

Solubility of D600-0649

Solubility Sources

Storage Condition of D600-0649

Storage Condition Sources

MSDS Information

MSDS Sources

Quality Control and Spectral Data

QC Reports Sources

Mechanism and Indications

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Cancer
Indications

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase

Chemical Information

M.Wt Formula CAS No. Synonyms
366.8 C19H15ClN4O2 1160266-14-7

Structure Information of D600-0649

Smiles C1C=CC(NC2N3C=CN=CC3=NC=2C2C=C(OC)C(O)=CC=2)=CC=1Cl
InChI InChI=1S/C19H15ClN4O2/c1-26-16-9-12(5-6-15(16)25)18-19(22-14-4-2-3-13(20)10-14)24-8-7-21-11-17(24)23-18/h2-11,22,25H,1H3

Related Products

Other Form Products of D600-0649

Name CAS Formula Suppliers

Recommended Products in Same Target

Name CAS Formula Suppliers
LY2857785 1619903-54-6 C26H36N6O 12
THZ2 1604810-84-5 C31H28ClN7O2 10
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 22
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 5
ML167 1285702-20-6 C19H17N3O3 15
AMG 925 1401033-86-0 C26H29N7O2 15
LDC000067 1073485-20-7 C18H18N4O3S 11
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 8
LEE011 (succinate) 1374639-75-4 C27H36N8O5 9
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 8
LEE011 1211441-98-3 C23H30N8O 21
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 6
Wogonin 632-85-9 C16H12O5 28
1-NM-PP1 221244-14-0 C20H21N5 17
WHI-P180 211555-08-7 C16H15N3O3 13
THZ1 1604810-83-4 C31H28ClN7O2 18
Senexin A 1366002-50-7 C17H14N4 8
CDK4-IN-1 1256963-02-6 C22H29ClN8 9
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 16
Purvalanol B 212844-54-7 C20H25ClN6O3 22

Recommended Products in the Same Indication

Name CAS Formula Suppliers

Chemical and Physical Properties

Appearance: Melting point:
Boiling point: Flash Point:
Water Solubility: Solubility:
Density: Merck:
BRN: Refractive Index:
Vapour: EINECS:
Optical Rotation: alpha:

Reference

[1].He LJ, et al. Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes. Bioorg Med Chem Lett. 2019 Feb 15;29(4):549-555.
With the aim of discovering novel cyclin-dependent kinase 8 (CDK8) inhibitors, a combined similarity search and molecular docking approach was employed, which led to 32 hits. Biological tests led to the discovery of several novel submicromolar inhibitors. In particular, compound C768-0769 (ZC0201) showed good CDK8 inhibitory activity, and compound ZC0201 effectively suppressed HCT-116 colorectal cancer cell proliferation by inducing G1/S transition arrest. Furthermore, modulation of phosphorylated signal transducer and activator of transcription 1 (Ser 727) (STAT1SER727), a pharmacodynamic biomarker of CDK8 activity, demonstrated that ZC0201 may cause G1/S transition arrest through CDK8 activity inhibition. Due to its good cellular activity, ZC0201 may be an ideal lead compound for further modification as a potential cancer therapeutic agent.

Tags: buy D600-0649 | D600-0649 IC50 | D600-0649 price | D600-0649 cost | D600-0649 solubility | D600-0649 purchase | D600-0649 manufacturer | D600-0649 research buy | D600-0649 order | D600-0649 MSDS | D600-0649 chemical structure | D600-0649 Storage condition | D600-0649 molecular weight | D600-0649 mw | D600-0649 datasheet | D600-0649 supplier | D600-0649 cell line | D600-0649 NMR | D600-0649 MS | D600-0649 IR | D600-0649 solubility | D600-0649 Safe information | D600-0649 Qc and Spectral Information | D600-0649 Clinical Information | D600-0649 Clinical Trial | D600-0649 Route of Synthesis | D600-0649 storage condition | D600-0649 diseases and conditions | D600-0649 flash point | D600-0649 boiling point | D600-0649 melting point | D600-0649 storage condition | D600-0649 brand